Director Stan Smith filed a Form 4 with the SEC on November 17, 2026, disclosing two open-market purchases of MAIA Biotechnology, Inc. common stock totaling 100,000 shares made on November 13 and November 16, 2026.
Key Highlights
- First purchase: 81,218 shares of common stock acquired on November 13, 2026, at $1 per share, held indirectly through The Stan V. Smith Trust Dated 1993.
- Second purchase: 18,782 shares of common stock acquired on November 16, 2026, at $1 per share, also held through the same trust.
- Post-transaction trust holdings: 1,619,178 shares beneficially owned through The Stan V. Smith Trust Dated 1993 following both transactions.
- Additional indirect holdings: Three separate accounts each hold 4,580 shares on behalf of family members, with Smith disclaiming beneficial ownership of those shares except to the extent of his pecuniary interest.
- Transaction codes: Both transactions are coded "P" (open-market purchase) with no Rule 10b5-1 plan box checked.
Stan Smith's Two-Day Purchase of MAIA Biotechnology Common Stock
According to the filing, Stan Smith, identified as a director of MAIA Biotechnology, Inc. (NYSE American:MAIA), acquired a combined 100,000 shares of the company's common stock across two trading days. The first transaction, on November 13, 2026, involved a purchase of 81,218 shares at $1 per share. The second transaction, on November 16, 2026, covered the remaining 18,782 shares, also at $1 per share. Both purchases are coded "P," indicating open-market transactions, and both are held indirectly through The Stan V. Smith Trust Dated 1993.
Following the two reported purchases, the filing discloses that Smith beneficially owns 1,619,178 shares through The Stan V. Smith Trust Dated 1993. In addition, the filing reports three separate blocks of 4,580 shares each, held indirectly through Illinois Uniform Transfers to Minors Act accounts for three named family members: Blake Sarai Teitei Smith, Gage Quentin Smith, and Travis Deo Zai Zai Smith. The filing states that Smith "disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein" for each of those three accounts.
No derivative securities transactions were reported in Table II of the filing. The form was signed by Stan V. Smith and dated November 17, 2026, the same date it was filed with the SEC.
What Was Disclosed
Director Stan Smith disclosed two open-market purchases of MAIA Biotechnology common stock on November 13 and November 16, 2026, totaling 100,000 shares at $1 per share, held through a trust, bringing his indirect beneficial ownership in that trust to 1,619,178 shares.



Please wait processing your request...